
## **Georg Goliasch**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5372425/publications.pdf Version: 2024-02-01



CEORC COLLASCH

#	Article	IF	CITATIONS
1	Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. European Heart Journal, 2018, 39, 39-46.	1.0	261
2	Natural History of FunctionalÂTricuspidÂRegurgitation. JACC: Cardiovascular Imaging, 2019, 12, 389-397.	2.3	102
3	Familial-combined hyperlipidaemia in very young myocardial infarction survivors (<=40 years of) Tj ETQq1 1 C	).784314 rş 1.0	gBT/Overlock 92
4	A Unifying Concept for the QuantitativeÂAssessment of SecondaryÂMitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 2506-2517.	1.2	86
5	Evolution of outcome and complications in TAVR: a meta-analysis of observational and randomized studies. Scientific Reports, 2020, 10, 15568.	1.6	60
6	Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (â‰ <b>8</b> €f40â€fyears of age). European Journal of Clinical Investigation, 2012, 42, 631-636.	1.7	59
7	Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. Journal of Clinical Lipidology, 2015, 9, 801-806.e1.	0.6	45
8	Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. European Heart Journal, 2020, 41, 2799-2810.	1.0	45
9	Evolution of secondary mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2018, 19, 622-629.	0.5	40
10	Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2471-2476.	0.4	39
11	A machine learning algorithm supports ultrasound-naÃ <sup>-</sup> ve novices in the acquisition of diagnostic echocardiography loops and provides accurate estimation of LVEF. International Journal of Cardiovascular Imaging, 2021, 37, 577-586.	0.7	37
12	Disproportionate Functional MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2019, 12, 2088-2090.	2.3	32
13	Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. BMJ, The, 2021, 373, n1421.	3.0	32
14	Blood urea nitrogen has additive value beyond estimated glomerular filtration rate for prediction of long-term mortality in patients with acute myocardial infarction. European Journal of Internal Medicine, 2019, 59, 84-90.	1.0	28
15	Principal Morphomic and FunctionalÂComponents of Secondary MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2021, 14, 2288-2300.	2.3	26
16	Increased resting heart rate and prognosis in treatmentâ€naÃ⁻ve unselected cancer patients: results from a prospective observational study. European Journal of Heart Failure, 2020, 22, 1230-1238.	2.9	23
17	The inflammationâ€based modified Glasgow prognostic score is associated with survival in stable heart failure patients. ESC Heart Failure, 2020, 7, 654-662.	1.4	23
18	Immunomodulatory treatment for lymphocytic myocarditis—a systematic review and meta-analysis. Heart Failure Reviews, 2018, 23, 573-581.	1.7	22

#	Article	IF	CITATIONS
19	A Contemporary Definition of Periprocedural Myocardial Injury After Percutaneous Coronary Intervention of Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2019, 12, 1915-1923.	1.1	22
20	Syncope. JACC: Cardiovascular Imaging, 2019, 12, 225-232.	2.3	22
21	Impaired antioxidant HDL function is associated with premature myocardial infarction. European Journal of Clinical Investigation, 2015, 45, 731-738.	1.7	21
22	Papillary Muscle Dyssynchrony-Mediated Functional Mitral Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 1728-1737.	2.3	21
23	Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 34.	2.7	20
24	Natural Course of Nonsevere Secondary Tricuspid Regurgitation. Journal of the American Society of Echocardiography, 2021, 34, 13-19.	1.2	19
25	Lipid profile and longâ€ŧerm outcome in premature myocardial infarction. European Journal of Clinical Investigation, 2018, 48, e13008.	1.7	18
26	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naÃ <sup>-</sup> ve cancer patients. Scientific Reports, 2019, 9, 2554.	1.6	18
27	Myocardial Angiotensin Metabolism in End-Stage HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1731-1743.	1.2	18
28	Long-term outcome and risk assessment in premature acute myocardial infarction: A 10-year follow-up study. International Journal of Cardiology, 2017, 240, 37-42.	0.8	15
29	Quantitative Definition of Severe Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2018, 72, 2934-2935.	1.2	15
30	Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement. European Heart Journal Cardiovascular Imaging, 2021, 22, 1045-1053.	0.5	14
31	Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery. Journal of the American Heart Association, 2017, 6, .	1.6	13
32	Increased concentrations of bioactive adrenomedullin subsequently to angiotensinâ€receptor/neprilysinâ€inhibitor treatment in chronic systolic heart failure. British Journal of Clinical Pharmacology, 2021, 87, 916-924.	1.1	13
33	Severe tricuspid regurgitation: prognostic role of right heart remodelling and pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2022, 23, 246-254.	0.5	12
34	Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. Frontiers in Cardiovascular Medicine, 2021, 8, 725903.	1.1	12
35	Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement. European Heart Journal Cardiovascular Imaging, 2021, 22, 1295-1303.	0.5	12
36	Malnutrition outweighs the effect of the obesity paradox. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1477-1486.	2.9	12

#	Article	IF	CITATIONS
37	Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	12
38	Refining Long-Term Prediction of Cardiovascular Risk in Diabetes – The VILDIA Score. Scientific Reports, 2017, 7, 4700.	1.6	11
39	Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure. European Journal of Clinical Investigation, 2019, 49, e13159.	1.7	10
40	GDFâ€15 in solid vs nonâ€solid treatmentâ€naÃ⁻ve malignancies. European Journal of Clinical Investigation, 2019, 49, e13168.	1.7	10
41	Polyunsaturated fatty acids supplementation impairs antiâ€oxidant highâ€density lipoprotein function in heart failure. European Journal of Clinical Investigation, 2018, 48, e12998.	1.7	9
42	Natural history of bivalvular functional regurgitation. European Heart Journal Cardiovascular Imaging, 2019, 20, 565-573.	0.5	9
43	Sex-Related Differences in Low-Gradient, Low–Ejection Fraction Aortic Stenosis. JACC: Cardiovascular Imaging, 2019, 12, 203-205.	2.3	9
44	Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation. JACC Basic To Translational Science, 2020, 5, 715-726.	1.9	9
45	Diagnostic assessment and procedural imaging for transcatheter edge-to-edge tricuspid valve repair: a step-by-step guide. European Heart Journal Cardiovascular Imaging, 2021, 22, 8-10.	0.5	9
46	Access site complications of postcardiotomy extracorporeal life support. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1546-1558.e8.	0.4	9
47	Fate of patients weaned from post-cardiotomy extracorporeal life support. European Journal of Cardio-thoracic Surgery, 2022, 61, 1178-1185.	0.6	9
48	Guideline directed <i>medical</i> therapy and reduction of secondary mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2022, 23, 755-764.	0.5	9
49	Volume Status Impacts CMR–Extracellular Volume Measurements and Outcome in AS Undergoing TAVR. JACC: Cardiovascular Imaging, 2021, 14, 516-518.	2.3	7
50	Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists. ESC Heart Failure, 2021, 8, 1408-1416.	1.4	7
51	Global regurgitant volume: approaching the critical mass in valvular-driven heart failure. European Heart Journal Cardiovascular Imaging, 2019, 21, 168-174.	0.5	5
52	Systematic Evaluation of Systemic Right Ventricular Function. Journal of Clinical Medicine, 2020, 9, 107.	1.0	5
53	The Paradox of Secondary Mitral Regurgitation. JACC: Cardiovascular Imaging, 2021, 14, 740-741.	2.3	5
54	Impact of sex on the management and outcome of aortic stenosis patients: a female aortic valve stenosis paradox, and a call for personalized treatments?. European Heart Journal, 2021, 42, 2692-2694.	1.0	5

#	Article	IF	CITATIONS
55	Heart Failure with Preserved Ejection Fraction after Leftâ€sided Valve Surgery: Prevalent and Relevant. European Journal of Heart Failure, 2021, , .	2.9	5
56	Relevance of Neutrophil Neprilysin in Heart Failure. Cells, 2021, 10, 2922.	1.8	5
57	Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. Journal of Personalized Medicine, 2022, 12, 320.	1.1	5
58	Aortic stenosis is an independent predictor for outcome in patients with in-hospital cardiac arrest. Resuscitation, 2019, 137, 156-160.	1.3	4
59	Secondary mitral regurgitation—Insights from microRNA assessment. European Journal of Clinical Investigation, 2021, 51, e13381.	1.7	4
60	Transcatheter treatment by valve-in-valve and valve-in-ring implantation for prosthetic tricuspid valve dysfunction. Wiener Klinische Wochenschrift, 2021, 133, 780-785.	1.0	4
61	Reply. Journal of the American College of Cardiology, 2019, 74, 1845-1847.	1.2	3
62	Left Main Coronary Artery Disease and Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions. Journal of Clinical Medicine, 2020, 9, 938.	1.0	3
63	Neprilysin inhibition does not alter dynamic of proenkephalinâ€A 119â€159 and proâ€substance P in heart failure. ESC Heart Failure, 2021, 8, 2016-2024.	1.4	3
64	Prognostic Value of Echocardiographic Right Ventricular Function Parameters in the Presence of Severe Tricuspid Regurgitation. Journal of Clinical Medicine, 2021, 10, 2266.	1.0	3
65	A Real World 10-Year Experience With Vascular Closure Devices and Large-Bore Access in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation. Frontiers in Cardiovascular Medicine, 2021, 8, 791693.	1.1	3
66	Circulating dipeptidyl peptidase (cDPP3)—A marker for endâ€stage heart failure?. Journal of Internal Medicine, 2022, 291, 886-890.	2.7	2
67	Transcatheter Versus Surgical Valve Repair in Patients with Severe Mitral Regurgitation. Journal of Personalized Medicine, 2022, 12, 90.	1.1	2
68	An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation. Journal of Personalized Medicine, 2020, 10, 233.	1.1	1
69	Tricuspid regurgitation secondary to heart failure: more pieces to solve the puzzle. European Journal of Heart Failure, 2020, 22, 1814-1816.	2.9	1
70	Interventional treatment of tricuspid regurgitation. Wiener Klinische Wochenschrift, 2020, 132, 57-60.	1.0	1
71	Clinical Impact of Pre-Procedural Percutaneous Coronary Intervention in Low- and Intermediate-Risk Transcatheter Aortic Valve Replacement Recipients. Journal of Personalized Medicine, 2021, 11, 633.	1.1	1
72	Secondary tricuspid regurgitation: neglected no more!. European Heart Journal Cardiovascular Imaging, 2021, 22, 166-167.	0.5	1

#	Article	IF	CITATIONS
73	The Authors Reply. JACC: Cardiovascular Imaging, 2019, 12, 1114.	2.3	Ο
74	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 1458.	2.3	0
75	Current Insights Into Secondary Mitral Regurgitation—Workup and Management. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	Ο
76	Simultaneous transcatheter mitral valve-in-mitral annular calcification and aortic valve-in-valve implantation: benefits of advanced multimodality imaging. European Heart Journal Cardiovascular Imaging, 2020, 21, 1433-1433.	0.5	0
77	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 891.	2.3	Ο
78	Percutaneous bail-out in severe acute mitral regurgitation: when surgery is not an option. European Heart Journal - Case Reports, 2021, 5, ytab207.	0.3	0
79	Durable Reduction of Mitral Regurgitation After 2 Years. JACC: Cardiovascular Interventions, 2021, 14, 1549-1550.	1.1	Ο
80	Mitral regurgitation tips the scales in acute or worsening heart failure. European Journal of Heart Failure, 2021, 23, 1763-1764.	2.9	0